Scholar Rock is awaiting a potential approval for its spinal muscular atrophy drug apitegromab, with a decision expected. The company has recently resubmitted its FDA filing and is expanding its manufacturing footprint, which may be seen as a strategic move or a response to regulatory risk. The outcome of the approval decision and its impact on the company's valuation and stock price are being closely watched by investors.